enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   Cobenfy offers new hope for people with schizophrenia, providing an innovative treatment option that could change how this condition is managed, according to Jelena Kunovac, MD, a board-certified ...

3. FDA approves new type of schizophrenia drug - AOL

   www.aol.com/news/fda-approves-type-schizophrenia...

   The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...

4. FDA Approves the First New Schizophrenia Drug in Decades - AOL

   www.aol.com/lifestyle/fda-approves-first...

   The medicine works in an entirely different way from existing treatments.

5. Schizophrenia In America - The Huffington Post

   highline.huffingtonpost.com/articles/en/stop-the...

   In McGorry’s conception, schizophrenia goes through a “prodrome” stage when symptoms gradually emerge, a “first episode” phase that covers, on average, the two years before the first break and finally a “chronic” phase when the disease causes a steady deterioration in many patients that can be difficult if not impossible to reverse.

6. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   The effectiveness of xanomeline/trospium chloride for the treatment of schizophrenia in adults was evaluated in two studies with identical designs. [2] Study 1 (NCT04659161) and study 2 (NCT04738123) were 5-week, randomized, double-blind, placebo-controlled, multi-center studies in adults with a diagnosis of schizophrenia according to DSM-5 ...

7. Ulotaront - Wikipedia

   en.wikipedia.org/wiki/Ulotaront

   The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [16] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [17]